|
Lorigerlimab Clinical Trials
3 actively recruiting trials across 2 locations
▲ +2 trials since August 2026
Also known as: MGD019
Pipeline
Phase 2: 3
Top Sponsors
- M.D. Anderson Cancer Center2
- MacroGenics1
Indications
- Cancer3
- High-risk Patients1
- Clear Cell Adenocarcinoma of Peritoneum1
- Clear Cell Adenocarcinoma of Fallopian Tube1
- Clear Cell Adenocarcinoma of Uterus1
Houston, Texas2 trials
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
MD Anderson Cancer Center
Phase 2
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M D Anderson Cancer Center
Phase 2
Los Angeles, California1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.